Investment Strategy Brief for May 18, 2026
As of May 18, 2026, Krafton's new release "Subnautica 2" has surpassed 2 million units sold within 12 hours, driving strong momentum in the K-Game sector. Meanwhile, Samsung Electronics is catching market attention after KB Securities raised its target price to 450,000 KRW, and in the biotech sector, ViGenCell’s consecutive selections for global conferences are seen as a positive signal. This report is based strictly on verified data available for specific stocks.
Investment Strategy Summary — May 2026-05-18
Large-Cap and Key Holdings Report
Samsung Electronics (005930)
KB Securities has maintained its "Buy" rating for Samsung Electronics while significantly raising its target price from 360,000 KRW to 450,000 KRW. The firm cited stronger-than-expected earnings growth despite strike concerns and forecasted memory supply shortages for next year as the primary drivers.
Krafton (259960)
Krafton achieved its highest-ever quarterly performance in Q1 2026, with 1.3714 trillion KRW in revenue and 561.6 billion KRW in operating profit, making it the leader in operating profit among K-Game companies. IP revenue exceeded 1 trillion KRW for the first time in a quarter, bolstered by brand collaborations and new content for the long-running 9-year-old IP, "Battlegrounds."
Additionally, its new underwater survival game, "Subnautica 2," has proven its global appeal by selling 2 million units within 12 hours of its Early Access launch, receiving positive reviews from major international gaming media outlets.
Kakao (035720)
As of May 2026, Kakao's stock continues to trend downward despite posting record-high Q1 earnings. Target prices are being slashed by nearly half, and the decoupling between financial improvements and stock price remains a key concern.
⚠️ The Samsung Electronics report mentioned above was published on 2026-05-15 and falls on the edge of the coverage period (after 2026-05-16). Other items are processed based on verified dates.
Biotech and Tech Growth Stock Analysis
ViGenCell (399160)
The Phase 2 clinical trial results for ViGenCell’s NK/T-cell lymphoma treatment, "VT-EBV-N," have been selected for an Oral Presentation at the European Hematology Association (EHA 2026). This follows their selection for an oral presentation at the American Society of Clinical Oncology (ASCO), highlighting the global academic community's continued interest in their cell therapy clinical capabilities.
Seegene (096530)
As of Q1 2026, Seegene has confirmed a trend of profitability recovery following the COVID-19 pandemic. Margin recovery in the non-respiratory segment is evident, with the operating profit margin rising to the 18% range, maintaining a surplus for two consecutive years. This first quarter is considered a foundation for value-up.
Krafton (IT Growth Perspective)
As mentioned in the large-cap section, the global success of "Subnautica 2" and record quarterly earnings highlight Krafton as the stock with the clearest earnings momentum among domestic game and IT growth stocks. Positive reviews from foreign gaming media also support the potential for continuous IP expansion.
Industrial and Energy Sector Strategy
Based on currently accessible research, no new securities analysis reports for major stocks in the industrial/energy sectors—such as Hanwha Ocean, SungEel HiTech, and DL E&C—have been confirmed since May 17, 2026.
While consensus and stock information pages for Hanwha Ocean (042660) were checked, no specific changes to target prices or investment ratings published within the last 24 hours were found.
📌 Awaiting Data — Latest analyst reports (2026-05-17~18) for industrial sector stocks like Hanwha Ocean and SungEel HiTech are currently unavailable. These will be reflected in the next update.
Overall Investment Direction
Summary of investment direction based on currently verified data:
- Krafton (Pro-Buy): Record Q1 performance + early global success of "Subnautica 2." Evaluated as the stock with the strongest short-term momentum.
- Samsung Electronics (Maintain Buy): KB Securities raised the target price from 360k to 450k KRW. Potential for further upside as the memory supply shortage cycle begins.
- Seegene (Continue Observation): Profitability recovery confirmed; foundation for value-up is being built, but further momentum needs verification.
- ViGenCell (Mid-to-Long Term Hold): Global clinical credibility is rising with consecutive oral presentations at ASCO and EHA. Focus on tracking mid-to-long-term clinical achievements rather than short-term price triggers.
- Kakao (Hold): Target prices continue to be lowered despite record Q1 earnings. Advising to refrain from new purchases until the cause of the decoupling between earnings and stock price is resolved.
- Hanwha Ocean, SungEel HiTech, etc. (Industrial/Energy): Awaiting data.
In general, the market in the 3rd week of May shows selective strength centered on the semiconductor, game, and biotech sectors, with the easing of external uncertainties following expectations for a U.S.-China summit acting as a driver for short-term gains.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
